<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9829">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715403</url>
  </required_header>
  <id_info>
    <org_study_id>1199.16</org_study_id>
    <nct_id>NCT00715403</nct_id>
  </id_info>
  <brief_title>A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120</brief_title>
  <official_title>Extension Study to Establish Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Patients With Previous Clinical Benefit From BIBF 1120</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>France: AFFSAPS</authority>
    <authority>Germany: Bundesinstitut fuer Arzneimittel und Medizinprodukte</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to evaluate the long-term safety of BIBF 1120 in
      terms of incidence and intensity of Adverse Events and changes in safety laboratory
      parameters.

      Secondary objectives are the collection of further safety data (vital signs), efficacy data
      and the determination of pharmacokinetic characteristics during long-term therapy with BIBF
      1120.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 1</measure>
    <time_frame>From signing the informed consent until final follow-up, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>All patients who had grade 1 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 2</measure>
    <time_frame>From signing the informed consent until final follow-up, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>All patients who had grade 2 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 3</measure>
    <time_frame>From signing the informed consent until final follow-up, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>All patients who had grade 3 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 4</measure>
    <time_frame>From signing the informed consent until final follow-up, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>All patients who had grade 4 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 5</measure>
    <time_frame>From signing the informed consent until final follow-up, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>All patients who had grade 5 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference From Baseline for Liver Enzymes</measure>
    <time_frame>From signing the informed consent until end of treatment, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference From Baseline for Bilirubin, Creatinine and Glucose</measure>
    <time_frame>From signing the informed consent until end of treatment, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference From Baseline for Haemoglobin</measure>
    <time_frame>From baseline until end of treatment, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Difference from baseline for Haemoglobin (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference From Baseline for Haematology and Differentials Parameters</measure>
    <time_frame>From signing the informed consent until end of treatment, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference From Baseline for Coagulation Parameters</measure>
    <time_frame>From signing the informed consent until end of treatment, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Difference from baseline (normalized value) in coagulation parameters Prothrombin time, international normalised ratio (PT-INR) and partial thromboplastin time. Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference From Baseline for Electrolytes</measure>
    <time_frame>From signing the informed consent until end of treatment, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically Relevant Abnormalities for Vital Signs</measure>
    <time_frame>From baseline until final follow-up, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinically relevant abnormalities for Vital Signs (systolic blood pressure, diastolic blood pressure, and pulse rate). New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Concentration of Nintedanib in Plasma at Steady-state (Cpre,ss)</measure>
    <time_frame>Just before drug administration every 28Â±7 days after day 29</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cpre,ss represents the pre-dose concentration of Nintedanib in Plasma at steady-state at day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unconfirmed Best Overall Response</measure>
    <time_frame>Baseline until end of treatment, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unconfirmed best overall response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0).
PD = Progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unconfirmed Best Objective Response</measure>
    <time_frame>Baseline until end of treatment, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unconfirmed best objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit</measure>
    <time_frame>Baseline until end of treatment, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical benefit was defined as the absence of disease progression (no PD or nonevaluable clinically progressive disease) determined by RECIST (version 1.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Objective Response</measure>
    <time_frame>Baseline until end of treatment, up to 991 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Confirmed objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>First drug administration (in previous trial) until end of treatment, up to 1230 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants that experienced progression free survival (PFS), assessed by RECIST (Response Evaluation Criteria In Solid Tumours) (version 1.0), by day 1230. Progression was defined as progressive disease (PD) or non-evaluable clinically progressive disease.
PFS was defined for patients without PD at screening as the time from first treatment with the trial drug in the previous trial until onset of PD or death, whatever comes earlier.
Patients with PD could enter the trial if they showed signs of clinical benefit. For patients with PD at screening, the RECIST assessment at screening was used as a new baseline value and PFS was the time from first treatment with the trial drug in this trial until the onset of progressive disease in this trial or death, whatever comes first.</description>
  </secondary_outcome>
  <enrollment type="Actual">41</enrollment>
  <condition>Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients with advanced solid tumours who have completed a previous
             study with BIBF 1120. The patients should not have progression of their underlying
             tumour disease unless there is evidence for significant clinical benefit (e.g.
             symptom improvement) from treatment with BIBF 1120.

          2. Age 18 years or older

          3. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score &lt;= 2

          4. Patients must have given written informed consent (which must be consistent with
             ICH-GCP and local legislation)

        Exclusion Criteria:

          1. Time elapsed from last administration of BIBF 1120 in the previous trial to start of
             treatment in the present trial exceeds four weeks

          2. Presence of drug related toxicity &gt; grade 2 CTC from previous therapy with BIBF 1120
             or presence of drug related continuous toxicity of grade 2 for seven or more
             consecutive days which would preclude ongoing chronic therapy with BIBF 1120

          3. Active ulcers (gastro-intestinal tract, skin)

          4. Major injuries and surgery within the past three weeks with incomplete wound healing

          5. Hypersensitivity to BIBF 1120 or the excipients of the trial drug

          6. Known secondary malignancy requiring therapy

          7. Active infectious disease

          8. Significant cardiovascular diseases (i.e. uncontrolled severe hypertension, unstable
             angina pectoris, history of myocardial infarction, congestive heart failure &gt; NYHA
             II)

          9. Gastrointestinal disorders anticipated to interfere with the resorption of the study
             drug

         10. Brain metastases requiring therapy

         11. Absolute neutrophil count less than 1,500/mm3

         12. Platelet count less than 100,000/mm3

         13. Bilirubin greater than 1.5 mg/dl (&gt; 26 Âµmol/L)

         14. Aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than
             2.5 times the upper limit of normal (if related to liver metastases greater than five
             times the upper limit of normal)

         15. Serum creatinine greater than 2 mg/dl (&gt; 176 Âµmol/L)

         16. Concomitant non-oncological diseases which are considered relevant for the evaluation
             of the safety of the trial drug

         17. Chemo-, radio-, or immunotherapy within the past four weeks prior to treatment with
             the trial drug

         18. Patients who are sexually active and unwilling to use a medically acceptable method
             of contraception

         19. Pregnancy or lactation

         20. Treatment with other investigational drugs or participation in another clinical trial
             within the past four weeks before start of therapy (visit 2) or concomitantly with
             this trial (except for a previous study with BIBF 1120)

         21. Patients unable to comply with the protocol

         22. Active alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1199.16.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bordeaux cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.16.3311A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clichy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.16.3311B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clichy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.16.3313A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.16.3313E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.16.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris cedex 15</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.16.3312A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.16.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg/Breisgau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.16.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grosshansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.16.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>TÃ¼bingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.16.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 24, 2014</lastchanged_date>
  <firstreceived_date>July 11, 2008</firstreceived_date>
  <firstreceived_results_date>November 14, 2014</firstreceived_results_date>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a multinational, open-label, uncontrolled, extension trial with Nintedanib in patients who had experienced a clinical benefit with Nintedanib (objective tumour response or disease stabilisation and/or symptom improvement) in either one out of five phase I or phase I/IIA clinical trials for advanced solid tumours at study entry.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>50mg QD</title>
          <description>Patients were treated with 50 mg Nintedanib once daily (QD) in the morning.</description>
        </group>
        <group group_id="P2">
          <title>200mg QD</title>
          <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
        </group>
        <group group_id="P3">
          <title>100mg BID</title>
          <description>Patients were treated with 100 mg Nintedanib twice daily (BID).</description>
        </group>
        <group group_id="P4">
          <title>150mg BID</title>
          <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
        </group>
        <group group_id="P5">
          <title>200mg BID</title>
          <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
        </group>
        <group group_id="P6">
          <title>250mg BID</title>
          <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
        </group>
        <group group_id="P7">
          <title>300mg BID</title>
          <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dose limiting Toxicity (DLT)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Adverse Event than DLT</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set which comprised of all patients who received at least one dose of Nintedanib in both their previous Nintedanib trial and in this extension trial</population>
      <group_list>
        <group group_id="B1">
          <title>50mg QD</title>
          <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
        </group>
        <group group_id="B2">
          <title>200mg QD</title>
          <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
        </group>
        <group group_id="B3">
          <title>100mg BID</title>
          <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
        </group>
        <group group_id="B4">
          <title>150mg BID</title>
          <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
        </group>
        <group group_id="B5">
          <title>200mg BID</title>
          <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
        </group>
        <group group_id="B6">
          <title>250mg BID</title>
          <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
        </group>
        <group group_id="B7">
          <title>300mg BID</title>
          <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="9"/>
                <measurement group_id="B5" value="6"/>
                <measurement group_id="B6" value="19"/>
                <measurement group_id="B7" value="1"/>
                <measurement group_id="B8" value="41"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="75.0" lower_limit="75" upper_limit="75"/>
                <measurement group_id="B2" value="47.0" lower_limit="47" upper_limit="47"/>
                <measurement group_id="B3" value="65.5" lower_limit="52" upper_limit="75"/>
                <measurement group_id="B4" value="66.0" lower_limit="52" upper_limit="78"/>
                <measurement group_id="B5" value="63.5" lower_limit="45" upper_limit="74"/>
                <measurement group_id="B6" value="66.0" lower_limit="41" upper_limit="80"/>
                <measurement group_id="B7" value="67.0" lower_limit="67" upper_limit="67"/>
                <measurement group_id="B8" value="66.0" lower_limit="41" upper_limit="80"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="2"/>
                <measurement group_id="B5" value="2"/>
                <measurement group_id="B6" value="1"/>
                <measurement group_id="B7" value="0"/>
                <measurement group_id="B8" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="7"/>
                <measurement group_id="B5" value="4"/>
                <measurement group_id="B6" value="18"/>
                <measurement group_id="B7" value="1"/>
                <measurement group_id="B8" value="33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 1</title>
        <description>All patients who had grade 1 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
        <time_frame>From signing the informed consent until final follow-up, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="19"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 1</title>
            <description>All patients who had grade 1 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Dyspepsia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="33"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nasopharyngitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="33"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anorexia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="16"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyperhidrosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhoea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="44"/>
                  <measurement group_id="O5" value="50"/>
                  <measurement group_id="O6" value="37"/>
                  <measurement group_id="O7" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bronchitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eye disorder</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eyelid oedema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Haemorrhoids</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Toothache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pyrexia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Muscle spasms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neck pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain in extremity</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vulvovaginal dryness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arrhythmia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="33"/>
                  <measurement group_id="O5" value="67"/>
                  <measurement group_id="O6" value="21"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="33"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Abdominal pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="33"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Tooth discolouration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Asthenia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="33"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Xerosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bone pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="50"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dizziness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anxiety</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rales</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nail disorder</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hot flush</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vertigo</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Constipation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="16"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flatulence</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastric disorder</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypersensitivity</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Viral infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Musculoskeletal pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Balance disorder</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sciatica</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dysuria</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dyspnoea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="33"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash maculo-papular</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sinus tachycardia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eye pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visual impairment</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Abdominal distension</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Adverse drug reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chest pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chills</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hepatic pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urinary tract infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Weight decreased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyperglycaemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Muscular weakness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Back pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Joint swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dysgeusia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Insomnia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Haematuria</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Incontinence</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cough</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alopecia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dry skin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pruritus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Conjunctivitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Haemoptysis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Relevant Abnormalities for Vital Signs</title>
        <description>Clinically relevant abnormalities for Vital Signs (systolic blood pressure, diastolic blood pressure, and pulse rate). New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
        <time_frame>From baseline until final follow-up, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="19"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinically Relevant Abnormalities for Vital Signs</title>
            <description>Clinically relevant abnormalities for Vital Signs (systolic blood pressure, diastolic blood pressure, and pulse rate). New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                  <measurement group_id="O2" value="0.0"/>
                  <measurement group_id="O3" value="0.0"/>
                  <measurement group_id="O4" value="0.0"/>
                  <measurement group_id="O5" value="0.0"/>
                  <measurement group_id="O6" value="0.0"/>
                  <measurement group_id="O7" value="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Concentration of Nintedanib in Plasma at Steady-state (Cpre,ss)</title>
        <description>Cpre,ss represents the pre-dose concentration of Nintedanib in Plasma at steady-state at day 29</description>
        <time_frame>Just before drug administration every 28Â±7 days after day 29</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set. No descriptive statistics could be calculated for the dosing groups 50 mg and 200 mg QD; 100 mg and 300 mg BID due to insufficient patients.</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="2"/>
                  <measurement group_id="O6" value="7"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pre-dose Concentration of Nintedanib in Plasma at Steady-state (Cpre,ss)</title>
            <description>Cpre,ss represents the pre-dose concentration of Nintedanib in Plasma at steady-state at day 29</description>
            <units>ng/mL</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4" value="7.54" spread="48.3"/>
                  <measurement group_id="O5" value="11.8" spread="33.5"/>
                  <measurement group_id="O6" value="11.0" spread="48.5"/>
                  <measurement group_id="O7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unconfirmed Best Overall Response</title>
        <description>Unconfirmed best overall response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0).
PD = Progressive disease.</description>
        <time_frame>Baseline until end of treatment, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="19"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Unconfirmed Best Overall Response</title>
            <description>Unconfirmed best overall response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0).
PD = Progressive disease.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Complete response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Partial response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable disease</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="75"/>
                  <measurement group_id="O4" value="33"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="16"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-evaluable, clinically non-progressive disease</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="83"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PD or non-evaluable , clinically PD</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="32"/>
                  <measurement group_id="O7" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unknown</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="44"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="42"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unconfirmed Best Objective Response</title>
        <description>Unconfirmed best objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)</description>
        <time_frame>Baseline until end of treatment, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="19"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Unconfirmed Best Objective Response</title>
            <description>Unconfirmed best objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="56"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="53"/>
                  <measurement group_id="O7" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unknown</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="44"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="42"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit</title>
        <description>Clinical benefit was defined as the absence of disease progression (no PD or nonevaluable clinically progressive disease) determined by RECIST (version 1.0).</description>
        <time_frame>Baseline until end of treatment, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="19"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Benefit</title>
            <description>Clinical benefit was defined as the absence of disease progression (no PD or nonevaluable clinically progressive disease) determined by RECIST (version 1.0).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="100"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="89"/>
                  <measurement group_id="O7" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Confirmed Objective Response</title>
        <description>Confirmed objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)</description>
        <time_frame>Baseline until end of treatment, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="19"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Confirmed Objective Response</title>
            <description>Confirmed objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="56"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="58"/>
                  <measurement group_id="O7" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unknown</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="44"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="42"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Percentage of participants that experienced progression free survival (PFS), assessed by RECIST (Response Evaluation Criteria In Solid Tumours) (version 1.0), by day 1230. Progression was defined as progressive disease (PD) or non-evaluable clinically progressive disease.
PFS was defined for patients without PD at screening as the time from first treatment with the trial drug in the previous trial until onset of PD or death, whatever comes earlier.
Patients with PD could enter the trial if they showed signs of clinical benefit. For patients with PD at screening, the RECIST assessment at screening was used as a new baseline value and PFS was the time from first treatment with the trial drug in this trial until the onset of progressive disease in this trial or death, whatever comes first.</description>
        <time_frame>First drug administration (in previous trial) until end of treatment, up to 1230 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set. Data for category</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="19"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression Free Survival</title>
            <description>Percentage of participants that experienced progression free survival (PFS), assessed by RECIST (Response Evaluation Criteria In Solid Tumours) (version 1.0), by day 1230. Progression was defined as progressive disease (PD) or non-evaluable clinically progressive disease.
PFS was defined for patients without PD at screening as the time from first treatment with the trial drug in the previous trial until onset of PD or death, whatever comes earlier.
Patients with PD could enter the trial if they showed signs of clinical benefit. For patients with PD at screening, the RECIST assessment at screening was used as a new baseline value and PFS was the time from first treatment with the trial drug in this trial until the onset of progressive disease in this trial or death, whatever comes first.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Progression (RECIST)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="33"/>
                  <measurement group_id="O6" value="42"/>
                  <measurement group_id="O7" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="32"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No progressive disease (RECIST) or death</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="75"/>
                  <measurement group_id="O4" value="44"/>
                  <measurement group_id="O5" value="67"/>
                  <measurement group_id="O6" value="16"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unknown</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="45"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="10"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 2</title>
        <description>All patients who had grade 2 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
        <time_frame>From signing the informed consent until final follow-up, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="19"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 2</title>
            <description>All patients who had grade 2 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anorexia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhoea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="33"/>
                  <measurement group_id="O6" value="21"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bronchitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Abdominal pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Asthenia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bone pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Constipation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flatulence</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Musculoskeletal pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sciatica</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dyspnoea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chest pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urinary tract infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Weight decreased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Back pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cough</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Haemoptysis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Osteoarthritis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Parotitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Osteolysis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Abdominal pain upper</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal disorder</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Groin pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="17"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anaemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neutropenia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Oedema peripheral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gammaâglutamyltransferase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dehydration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Productive cough</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Deep vein thrombosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Phlebitis superficial</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 3</title>
        <description>All patients who had grade 3 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
        <time_frame>From signing the informed consent until final follow-up, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="19"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 3</title>
            <description>All patients who had grade 3 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Gammaâglutamyltransferase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhoea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhoea infectious</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dyspnoea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lymphopenia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Constipation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Haemorrhoids</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ileus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subileus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pneumonia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Convulsion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Renal failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="11"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urinary tract obstruction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pleural effusion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 4</title>
        <description>All patients who had grade 4 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
        <time_frame>From signing the informed consent until final follow-up, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="19"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 4</title>
            <description>All patients who had grade 4 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 5</title>
        <description>All patients who had grade 5 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
        <time_frame>From signing the informed consent until final follow-up, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="19"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence and Intensity of Adverse Events With Highest CTCAE Grade 5</title>
            <description>All patients who had grade 5 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Subdural Haematoma</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="5"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Malignant neoplasm progression</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="26"/>
                  <measurement group_id="O7" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference From Baseline for Liver Enzymes</title>
        <description>Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
        <time_frame>From signing the informed consent until end of treatment, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="18"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Difference From Baseline for Liver Enzymes</title>
            <description>Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
            <units>U/L</units>
            <param>Median</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Alkaline phosphatase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127.0" spread="0.0"/>
                  <measurement group_id="O2" value="11.9" spread="0.0"/>
                  <measurement group_id="O3" value="-39.0" spread="70.5"/>
                  <measurement group_id="O4" value="-21.2" spread="96.4"/>
                  <measurement group_id="O5" value="-11.7" spread="81.0"/>
                  <measurement group_id="O6" value="16.0" spread="180.9"/>
                  <measurement group_id="O7" value="7.2" spread="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Aspartate aminotransferase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.3" spread="0.0"/>
                  <measurement group_id="O2" value="13.7" spread="0.0"/>
                  <measurement group_id="O3" value="9.6" spread="18.0"/>
                  <measurement group_id="O4" value="6.8" spread="9.1"/>
                  <measurement group_id="O5" value="4.3" spread="41.0"/>
                  <measurement group_id="O6" value="15.9" spread="35.1"/>
                  <measurement group_id="O7" value="7.6" spread="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alanine aminotransferase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.6" spread="0.0"/>
                  <measurement group_id="O2" value="6.6" spread="0.0"/>
                  <measurement group_id="O3" value="0.6" spread="11.1"/>
                  <measurement group_id="O4" value="-1.6" spread="18.8"/>
                  <measurement group_id="O5" value="9.1" spread="45.4"/>
                  <measurement group_id="O6" value="17.0" spread="33.6"/>
                  <measurement group_id="O7" value="12.4" spread="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference From Baseline for Bilirubin, Creatinine and Glucose</title>
        <description>Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
        <time_frame>From signing the informed consent until end of treatment, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="18"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Difference From Baseline for Bilirubin, Creatinine and Glucose</title>
            <description>Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
            <units>mg/dL</units>
            <param>Median</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Bilirubin (total)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="0.0"/>
                  <measurement group_id="O2" value="0.0" spread="0.0"/>
                  <measurement group_id="O3" value="0.0" spread="0.2"/>
                  <measurement group_id="O4" value="0.0" spread="0.3"/>
                  <measurement group_id="O5" value="0.1" spread="0.1"/>
                  <measurement group_id="O6" value="0.1" spread="0.3"/>
                  <measurement group_id="O7" value="0.0" spread="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.1" spread="0.0"/>
                  <measurement group_id="O2" value="-0.3" spread="0.0"/>
                  <measurement group_id="O3" value="0.0" spread="0.2"/>
                  <measurement group_id="O4" value="-0.1" spread="0.0"/>
                  <measurement group_id="O5" value="-0.1" spread="0.2"/>
                  <measurement group_id="O6" value="-0.1" spread="0.3"/>
                  <measurement group_id="O7" value="0.0" spread="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose (N=1,1,3,9,4,14,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-60.0" spread="0.0"/>
                  <measurement group_id="O2" value="-2.2" spread="0.0"/>
                  <measurement group_id="O3" value="28.9" spread="126.1"/>
                  <measurement group_id="O4" value="-11.3" spread="75.1"/>
                  <measurement group_id="O5" value="-76.5" spread="75.9"/>
                  <measurement group_id="O6" value="-23.3" spread="52.2"/>
                  <measurement group_id="O7" value="-40.0" spread="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference From Baseline for Haemoglobin</title>
        <description>Difference from baseline for Haemoglobin (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
        <time_frame>From baseline until end of treatment, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="18"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Difference From Baseline for Haemoglobin</title>
            <description>Difference from baseline for Haemoglobin (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
            <units>g/dL</units>
            <param>Median</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.8" spread="0.0"/>
                  <measurement group_id="O2" value="1.4" spread="0.0"/>
                  <measurement group_id="O3" value="0.4" spread="2.3"/>
                  <measurement group_id="O4" value="1.0" spread="1.3"/>
                  <measurement group_id="O5" value="1.2" spread="0.7"/>
                  <measurement group_id="O6" value="-0.2" spread="2.1"/>
                  <measurement group_id="O7" value="1.1" spread="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference From Baseline for Haematology and Differentials Parameters</title>
        <description>Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
        <time_frame>From signing the informed consent until end of treatment, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="18"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Difference From Baseline for Haematology and Differentials Parameters</title>
            <description>Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
            <units>10^9 /L</units>
            <param>Median</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Platelets</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42.2" spread="0.0"/>
                  <measurement group_id="O2" value="11.1" spread="0.0"/>
                  <measurement group_id="O3" value="1.0" spread="83.7"/>
                  <measurement group_id="O4" value="-2.5" spread="25.2"/>
                  <measurement group_id="O5" value="-38.1" spread="39.9"/>
                  <measurement group_id="O6" value="11.2" spread="65.9"/>
                  <measurement group_id="O7" value="-27.1" spread="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White blood cell count</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.1" spread="0.0"/>
                  <measurement group_id="O2" value="-0.7" spread="0.0"/>
                  <measurement group_id="O3" value="0.2" spread="2.9"/>
                  <measurement group_id="O4" value="-0.8" spread="2.6"/>
                  <measurement group_id="O5" value="-0.1" spread="5.6"/>
                  <measurement group_id="O6" value="0.7" spread="2.9"/>
                  <measurement group_id="O7" value="0.0" spread="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lymphocytes (N=1,1,4,9,4,17,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.6" spread="0.0"/>
                  <measurement group_id="O2" value="-0.4" spread="0.0"/>
                  <measurement group_id="O3" value="-0.1" spread="2.0"/>
                  <measurement group_id="O4" value="1.0" spread="1.1"/>
                  <measurement group_id="O5" value="0.0" spread="1.6"/>
                  <measurement group_id="O6" value="0.6" spread="0.6"/>
                  <measurement group_id="O7" value="1.1" spread="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neutrophils (N=1,1,4,9,6,17,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.1" spread="0.0"/>
                  <measurement group_id="O2" value="-4.7" spread="0.0"/>
                  <measurement group_id="O3" value="0.9" spread="3.7"/>
                  <measurement group_id="O4" value="-1.0" spread="5.6"/>
                  <measurement group_id="O5" value="-2.4" spread="10.0"/>
                  <measurement group_id="O6" value="-0.5" spread="3.0"/>
                  <measurement group_id="O7" value="-1.2" spread="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference From Baseline for Coagulation Parameters</title>
        <description>Difference from baseline (normalized value) in coagulation parameters Prothrombin time, international normalised ratio (PT-INR) and partial thromboplastin time. Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
        <time_frame>From signing the informed consent until end of treatment, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="19"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Difference From Baseline for Coagulation Parameters</title>
            <description>Difference from baseline (normalized value) in coagulation parameters Prothrombin time, international normalised ratio (PT-INR) and partial thromboplastin time. Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
            <units>sec</units>
            <param>Median</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>PT-INR (N=1,1,3,7,5,14,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.1" spread="0.0"/>
                  <measurement group_id="O2" value="0.1" spread="0.0"/>
                  <measurement group_id="O3" value="0.3" spread="0.6"/>
                  <measurement group_id="O4" value="0.1" spread="0.1"/>
                  <measurement group_id="O5" value="0.2" spread="0.5"/>
                  <measurement group_id="O6" value="-0.0" spread="0.1"/>
                  <measurement group_id="O7" value="0.1" spread="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Partial thromboplastin time (N=1,1,3,9,4,14,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.7" spread="0.0"/>
                  <measurement group_id="O2" value="2.6" spread="0.0"/>
                  <measurement group_id="O3" value="-3.6" spread="6.7"/>
                  <measurement group_id="O4" value="1.9" spread="4.3"/>
                  <measurement group_id="O5" value="1.9" spread="4.3"/>
                  <measurement group_id="O6" value="1.5" spread="4.7"/>
                  <measurement group_id="O7" value="-2.9" spread="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference From Baseline for Electrolytes</title>
        <description>Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
        <time_frame>From signing the informed consent until end of treatment, up to 991 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>50mg QD</title>
            <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>200mg QD</title>
            <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>100mg BID</title>
            <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O4">
            <title>150mg BID</title>
            <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O5">
            <title>200mg BID</title>
            <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O6">
            <title>250mg BID</title>
            <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
          </group>
          <group group_id="O7">
            <title>300mg BID</title>
            <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="9"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="19"/>
                  <measurement group_id="O7" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Difference From Baseline for Electrolytes</title>
            <description>Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.</description>
            <units>mmol/L</units>
            <param>Median</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Potassium (N=1,1,4,9,6,18,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.2" spread="0.0"/>
                  <measurement group_id="O2" value="-0.3" spread="0.0"/>
                  <measurement group_id="O3" value="-0.3" spread="2.1"/>
                  <measurement group_id="O4" value="0.1" spread="0.4"/>
                  <measurement group_id="O5" value="-0.0" spread="1.1"/>
                  <measurement group_id="O6" value="0.1" spread="0.9"/>
                  <measurement group_id="O7" value="0.0" spread="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium (N=1,1,4,9,6,18,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" spread="0.0"/>
                  <measurement group_id="O2" value="1.0" spread="0.0"/>
                  <measurement group_id="O3" value="3.3" spread="5.2"/>
                  <measurement group_id="O4" value="0.0" spread="1.5"/>
                  <measurement group_id="O5" value="1.5" spread="6.0"/>
                  <measurement group_id="O6" value="-1.3" spread="5.5"/>
                  <measurement group_id="O7" value="5.0" spread="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first intake of trial medication until 28 days after last intake of medication, up to 1119 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>50mg QD</title>
          <description>Patients were treated with 50 mg Nintedanib once daily in the morning.</description>
        </group>
        <group group_id="E2">
          <title>200mg QD</title>
          <description>Patients were treated with 200 mg Nintedanib once daily in the morning.</description>
        </group>
        <group group_id="E3">
          <title>100mg BID</title>
          <description>Patients were treated with 100 mg Nintedanib twice daily.</description>
        </group>
        <group group_id="E4">
          <title>150mg BID</title>
          <description>Patients were treated with 150 mg Nintedanib twice daily.</description>
        </group>
        <group group_id="E5">
          <title>200mg BID</title>
          <description>Patients were treated with 200 mg Nintedanib twice daily.</description>
        </group>
        <group group_id="E6">
          <title>250mg BID</title>
          <description>Patients were treated with 250 mg Nintedanib twice daily.</description>
        </group>
        <group group_id="E7">
          <title>300mg BID</title>
          <description>Patients were treated with 300 mg Nintedanib twice daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Tooth discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Phlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BIâs intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
